-
1 Comment
ALK-Abelló A/S is currently in a long term uptrend where the price is trading 24.2% above its 200 day moving average.
From a valuation standpoint, the stock is 99.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 7.4.
ALK-Abelló A/S's total revenue rose by 12.2% to $991M since the same quarter in the previous year.
Its net income has dropped by 6.9% to $-31M since the same quarter in the previous year.
Finally, its free cash flow grew by 5.4% to $136M since the same quarter in the previous year.
Based on the above factors, ALK-Abelló A/S gets an overall score of 4/5.
Exchange | F |
---|---|
CurrencyCode | EUR |
ISIN | None |
Sector | Healthcare |
Industry | Biotechnology |
Beta | 0.32 |
---|---|
Market Cap | 82B |
PE Ratio | 2753.38 |
Target Price | None |
Dividend Yield | 0.0% |
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies. The company offers GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX for the treatment of allergic rhinitis; and ACARIZAX for treating allergic rhinitis and allergic asthma. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 4AJ.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025